We are thrilled to announce that Sanford-Burnham’s Board of Trustees has appointed Perry Nisen, MD, PhD, as the Institute’s chief executive officer and holder of the Donald Bren Chief Executive Chair. In this role, he will lead the Institute and oversee the execution of our new 10-year strategic vision to more quickly translate basic research discoveries into novel treatments that improve human health. Dr. Nisen joins us from GlaxoSmithKline (GSK) – a British multinational pharmaceutical company – where he was senior vice president of Science and Innovation. Continue reading “Sanford-Burnham announces next CEO”
Institute News